Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement
- PMID: 23582869
- PMCID: PMC3664537
- DOI: 10.1016/j.jaac.2012.12.006
Psychotropic medication treatment of adolescents: results from the National Comorbidity Survey-Adolescent Supplement
Abstract
Objective: To examine the 12-month prevalence of psychotropic medication use among adolescents, and the match between mental disorder diagnoses and past-year antidepressant and stimulant use.
Method: Data are from the National Comorbidity Survey-Adolescent Supplement (2002-2004), a nationally representative survey of 10,123 adolescents aged 13 to 18 years that assesses DSM-IV disorders using a fully structured diagnostic interview, a modified version of the World Health Organization Composite International Diagnostic Interview (CIDI). Rates of 12-month psychotropic medication use are stratified by respondent socio-demographic characteristics, and the distribution of 12-month DSM-IV CIDI disorders is estimated among past-12-month use of antidepressants and stimulants.
Results: During a 1-year period, 7.0% of adolescents used at least one psychotropic medication; these medications were most commonly antidepressants (3.9%), followed by stimulants (2.8%), anxiolytics (0.8%), antipsychotics (0.5%), and mood stabilizers (0.4%). Nearly three-quarters (74.1%) of adolescents with any past-year psychotropic medication use had at least one CIDI mental disorder, and many had disorders for which the specific medication class is clinically indicated. Among adolescents using antidepressants, 48.8% had a past-12-month depressive or anxiety disorder, and an additional 20.3% had a lifetime depressive or anxiety disorder. Nearly one-half (49.1%) of adolescents using stimulants met past-12-month attention-deficit/hyperactivity disorder (ADHD) criteria, and an additional 13.1% met lifetime criteria for ADHD.
Conclusions: Most adolescents who are treated with psychotropic medications have one or more psychiatric disorders and many, albeit far from all, have mental disorders for which the specific medications are clinically indicated.
Published by Elsevier Inc.
Similar articles
-
Medication use in US youth with mental disorders.JAMA Pediatr. 2013 Feb;167(2):141-8. doi: 10.1001/jamapediatrics.2013.431. JAMA Pediatr. 2013. PMID: 23403911
-
Psychotropic medication use among adolescents: United States, 2005-2010.NCHS Data Brief. 2013 Dec;(135):1-8. NCHS Data Brief. 2013. PMID: 24314102
-
Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.J Child Adolesc Psychopharmacol. 2014 Jun;24(5):260-8. doi: 10.1089/cap.2013.0107. Epub 2014 May 19. J Child Adolesc Psychopharmacol. 2014. PMID: 24839998
-
Recent international trends in psychotropic medication prescriptions for children and adolescents.Eur Child Adolesc Psychiatry. 2015 Jun;24(6):635-40. doi: 10.1007/s00787-014-0631-y. Epub 2014 Nov 8. Eur Child Adolesc Psychiatry. 2015. PMID: 25378107 Review.
-
Trends and Prevalence of Psychotropic Medication Use in Children and Adolescents in the Period Between 2013 and 2023: A Systematic Review.Cureus. 2024 Mar 3;16(3):e55452. doi: 10.7759/cureus.55452. eCollection 2024 Mar. Cureus. 2024. PMID: 38571846 Free PMC article. Review.
Cited by
-
Lifetime prevalence and treatment of mental disorders in Saudi youth and adolescents.Sci Rep. 2023 Apr 15;13(1):6186. doi: 10.1038/s41598-023-33005-5. Sci Rep. 2023. PMID: 37061556 Free PMC article.
-
Development of a Symptom-Focused Model to Guide the Prescribing of Antipsychotics in Children and Adolescents: Results of the First Phase of the Safer Use of Antipsychotics in Youth (SUAY) Clinical Trial.J Am Acad Child Adolesc Psychiatry. 2022 Jan;61(1):93-102. doi: 10.1016/j.jaac.2021.04.010. Epub 2021 May 4. J Am Acad Child Adolesc Psychiatry. 2022. PMID: 34256967 Free PMC article. Clinical Trial.
-
Psychiatric Comorbidities Are Highly Prevalent in Nonesophageal Eosinophilic Gastrointestinal Diseases.Clin Gastroenterol Hepatol. 2022 Apr;20(4):e664-e670. doi: 10.1016/j.cgh.2021.05.044. Epub 2021 May 28. Clin Gastroenterol Hepatol. 2022. PMID: 34058413 Free PMC article.
-
Evaluating quality in adolescent mental health services: a systematic review.BMJ Open. 2021 May 10;11(5):e044929. doi: 10.1136/bmjopen-2020-044929. BMJ Open. 2021. PMID: 33972340 Free PMC article.
-
Patterns of internalizing symptoms and disability functioning in children and adolescents.Eur Child Adolesc Psychiatry. 2022 Sep;31(9):1455-1464. doi: 10.1007/s00787-021-01789-4. Epub 2021 Apr 28. Eur Child Adolesc Psychiatry. 2022. PMID: 33909142
References
-
- Vitiello B, Zuvekas SH, Norquist GS. National estimates of antidepressant medication use among U.S. children, 1997–2002. J Am Acad Child Adolesc Psychiatry. 2006;45(3):271–279. - PubMed
-
- Zuvekas SH, Vitiello B, Norquist GS. Recent trends in stimulant medication use among U.S. children. Am J Psychiatry. 2006;163(4):579–585. - PubMed
-
- Olfson M, Blanco C, Liu L, Moreno C, Laje G. National trends in the outpatient treatment of children and adolescents with antipsychotic drugs. Arch Gen Psychiatry. 2006;63(6):679–685. - PubMed
-
- Weiss M, Worling D, Wasdell M. A chart review study of the inattentive and combined types of ADHD. J Atten Disord. 2003;7(1):1–9. - PubMed
-
- Zito JM, Safer DJ, dosReis S, et al. Rising prevalence of antidepressants among U.S. youths. Pediatrics. 2002;109(5):721–727. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
